Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Hoba Therapeutics
Seed Round in 2016
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Battersea Biotech
Seed Round in 2016
Battersea Biotech develops alternative cell types and technologies to overcome the shortcomings of current CAR-T and TCR technologies.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Nuevolution A/S is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. The company specializes in developing drug treatments for oncology and chronic inflammatory diseases. Nuevolution has created Chemetics®, an innovative drug discovery platform that combines wet chemistry and molecular biology to facilitate the rapid synthesis and screening of over one billion small molecule compounds. This technology allows for the efficient identification of potent drug candidates. The company's pipeline includes several programs such as ROR?t inhibitors and IL-17A inhibitors aimed at treating various diseases. Nuevolution collaborates with major pharmaceutical and biotechnology companies, entering into agreements with firms like Amgen and GlaxoSmithKline. Additionally, the company engages in contract research services, contributing to its revenue generation across multiple markets including Denmark, Sweden, and the USA. As a privately owned entity, Nuevolution is supported by key Scandinavian investors.
Nuevolution A/S is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. The company specializes in developing drug treatments for oncology and chronic inflammatory diseases. Nuevolution has created Chemetics®, an innovative drug discovery platform that combines wet chemistry and molecular biology to facilitate the rapid synthesis and screening of over one billion small molecule compounds. This technology allows for the efficient identification of potent drug candidates. The company's pipeline includes several programs such as ROR?t inhibitors and IL-17A inhibitors aimed at treating various diseases. Nuevolution collaborates with major pharmaceutical and biotechnology companies, entering into agreements with firms like Amgen and GlaxoSmithKline. Additionally, the company engages in contract research services, contributing to its revenue generation across multiple markets including Denmark, Sweden, and the USA. As a privately owned entity, Nuevolution is supported by key Scandinavian investors.